1. Home
  2. CBIO vs WILC Comparison

CBIO vs WILC Comparison

Compare CBIO & WILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.13

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

WILC

G. Willi-Food International Ltd.

HOLD

Current Price

$34.05

Market Cap

487.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
WILC
Founded
2003
1994
Country
United States
Israel
Employees
44
N/A
Industry
Food Distributors
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
557.8M
487.6M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
CBIO
WILC
Price
$18.13
$34.05
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$26.67
N/A
AVG Volume (30 Days)
269.6K
2.2K
Earning Date
04-29-2026
05-18-2026
Dividend Yield
N/A
2.70%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$279.20
N/A
P/E Ratio
N/A
$13.45
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$15.30
52 Week High
$27.41
$37.35

Technical Indicators

Market Signals
Indicator
CBIO
WILC
Relative Strength Index (RSI) 45.87 50.06
Support Level $16.31 $33.00
Resistance Level $21.60 $37.13
Average True Range (ATR) 1.78 1.17
MACD -0.30 -0.52
Stochastic Oscillator 27.80 35.29

Price Performance

Historical Comparison
CBIO
WILC

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About WILC G. Willi-Food International Ltd.

G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.

Share on Social Networks: